CL2024002683A1 - Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19 - Google Patents
Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19Info
- Publication number
- CL2024002683A1 CL2024002683A1 CL2024002683A CL2024002683A CL2024002683A1 CL 2024002683 A1 CL2024002683 A1 CL 2024002683A1 CL 2024002683 A CL2024002683 A CL 2024002683A CL 2024002683 A CL2024002683 A CL 2024002683A CL 2024002683 A1 CL2024002683 A1 CL 2024002683A1
- Authority
- CL
- Chile
- Prior art keywords
- protein
- immunogenic compositions
- covid
- prevention
- recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263318640P | 2022-03-10 | 2022-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002683A1 true CL2024002683A1 (es) | 2025-01-03 |
Family
ID=87936013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002683A CL2024002683A1 (es) | 2022-03-10 | 2024-09-06 | Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250186578A1 (https=) |
| EP (1) | EP4489779A2 (https=) |
| JP (1) | JP2025509352A (https=) |
| KR (1) | KR20240161963A (https=) |
| CN (1) | CN119317446A (https=) |
| AU (1) | AU2023231285A1 (https=) |
| CA (1) | CA3245533A1 (https=) |
| CL (1) | CL2024002683A1 (https=) |
| CO (1) | CO2024012344A2 (https=) |
| MX (1) | MX2024011049A (https=) |
| WO (1) | WO2023173032A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2251034T3 (pl) * | 2005-12-02 | 2018-07-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów |
| MX2022013934A (es) * | 2020-05-07 | 2023-02-22 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo. |
| US20250041402A1 (en) * | 2021-09-30 | 2025-02-06 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof |
-
2023
- 2023-03-09 CA CA3245533A patent/CA3245533A1/en active Pending
- 2023-03-09 CN CN202380026690.5A patent/CN119317446A/zh active Pending
- 2023-03-09 KR KR1020247033613A patent/KR20240161963A/ko active Pending
- 2023-03-09 EP EP23767708.3A patent/EP4489779A2/en active Pending
- 2023-03-09 AU AU2023231285A patent/AU2023231285A1/en active Pending
- 2023-03-09 JP JP2024553586A patent/JP2025509352A/ja active Pending
- 2023-03-09 WO PCT/US2023/064063 patent/WO2023173032A2/en not_active Ceased
- 2023-03-09 MX MX2024011049A patent/MX2024011049A/es unknown
- 2023-03-09 US US18/845,323 patent/US20250186578A1/en active Pending
-
2024
- 2024-09-06 CL CL2024002683A patent/CL2024002683A1/es unknown
- 2024-09-11 CO CONC2024/0012344A patent/CO2024012344A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119317446A (zh) | 2025-01-14 |
| EP4489779A2 (en) | 2025-01-15 |
| AU2023231285A1 (en) | 2024-07-25 |
| JP2025509352A (ja) | 2025-04-11 |
| US20250186578A1 (en) | 2025-06-12 |
| CA3245533A1 (en) | 2023-09-14 |
| KR20240161963A (ko) | 2024-11-13 |
| MX2024011049A (es) | 2024-09-18 |
| WO2023173032A2 (en) | 2023-09-14 |
| CO2024012344A2 (es) | 2024-12-30 |
| WO2023173032A3 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11046934B2 (en) | Mutations that confer genetic stability to additional genes in influenza viruses | |
| BR112022022604A2 (pt) | Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos | |
| US11241492B2 (en) | Mutations that confer genetic stability to genes in influenza viruses | |
| Nogales et al. | Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development | |
| Heaton et al. | In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies | |
| US20210299249A1 (en) | Recombinant multivalent influenza viruses | |
| EP4093415A1 (en) | Recombinant influenza viruses with stabilized na | |
| Zeng et al. | Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses | |
| Wirblich et al. | Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| CO2024012344A2 (es) | Virus de la enfermedad de newcastle recombinantes y composiciones inmunogénicas para su uso en la prevención de la covid-19 | |
| BR112022019949A2 (pt) | Vacina com base em vetor de poxvírus atenuado para proteção contra covid-19 | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| Luo et al. | Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus | |
| MX2021004859A (es) | Vacuna de ibv h52 con proteina espicular heterologa. | |
| WO2023196759A3 (en) | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant | |
| AR056133A1 (es) | Virus de influenza canina y composiciones relacionadas y metodos de uso | |
| CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
| AR124522A1 (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| MX2017008342A (es) | Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas. | |
| MX2023012595A (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv. | |
| AR085800A1 (es) | Vacuna de rinitis equina | |
| UY39916A (es) | Partículas de aav que comprenden una proteína de la cápside hepatotrópica y alfa-galactosidasa y su uso para tratar la enfermedad de fabry | |
| CU20200081A7 (es) | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |